Abstract
Poststroke depression (PSD) is a common sequelae of stroke, which has negative impact on the physical and cognitive function, dependency in activities of daily living, longer hospital stays, and rehabilitation outcomes. Furthermore, PSD may also be associated with an increased risk of morbidity and mortality including death by suicide. Rates of diagnosed and treated PSD in routine clinical practice are low due to difficulty in assessment and no standard diagnostic criteria. Regular screening of PSD in stroke patient using validated instruments is recommended. Early treatment and prevention of PSD with proper medication and rehabilitation appeared to improve not only depressive symptoms but also neurological impairment, dependence and disability after stroke. The active rehabilitation treatment for improving independence of patient's functional level is very important in management of PSD.
References
1. Parikh RM, Robinson RG, Lipsey JR, Starkstein SE, Fedoroff JP, Price TR. The impact of poststroke depression on recovery in activities of daily living over a 2-year follow-up. Arch Neurol. 1990; 47(7):785–789.
2. Hama S, Yamashita H, Yamawaki S, Kurisu K. Post-stroke depression and apathy: Interactions between functional recovery, lesion location, and emotional response. Psychogeriatrics. 2011; 11(1):68–76.
3. Robinson RG, Spalletta G. Poststroke Depression: A Review. Can J Psychiatry. 2010; 55(6):341–349.
4. Morris PL, Robinson RG, Samuels J. Depression, introversion and mortality following stroke. Aust N Z J Psychiatry. 1993; 27(3):443–449.
5. House A, Knapp P, Bamford J, Vail A. Mortality at 12 and 24 months after stroke may be associated with depressive symptoms at 1 month. Stroke. 2001; 32(3):696–701.
6. Herrmann N, Seitz D, Fischer H, Saposnik G, Calzavara A, Anderson G, et al. Detection and treatment of post stroke depression: results from the registry of the Canadian stroke network. Int J Geriatr Psychiatry. 2011; 26(11):1195–1200.
7. Spalletta G, Robinson RG. How should depression be diagnosed in patients with stroke? Acta Psychiatr Scand. 2010; 121(6):401–403.
8. Cumming TB, Churilov L, Skoog I, Blomstrand C, Linden T. Little evidence for different phenomenology in poststroke depression. Acta Psychiatr Scand. 2010; 121(6):424–430.
9. Capaldi VF 2nd, Wynn GH. Emerging strategies in the treatment of poststroke depression and psychiatric distress in patients. Psychol Res Behav Manag. 2010; 3:109–118.
10. Gainotti G, Azzoni A, Razzano C, Lanzillotta M, Marra C, Gasparini F. The Post-Stroke Depression Rating Scale: a test specifically devised to investigate affective disorders of stroke patients. J Clin Exp Neuropsychol. 1997; 19(3):340–356.
11. Healey AK, Kneebone II, Carroll M, Anderson SJ. A preliminary investigation of the reliability and validity of the Brief Assessment Schedule Depression Cards and the Beck Depression Inventory-Fast Screen to screen for depression in older stroke survivors. Int J Geriatr Psychiatry. 2008; 23(5):531–536.
12. Bennett HE, Thomas SA, Austen R, Morris AM, Lincoln NB. Validation of screening measures for assessing mood in stroke patients. Br J Clin Psychol. 2006; 45(Pt 3):367–376.
13. Whyte EM, Mulsant BH. Post stroke depression: epidemiology, pathophysiology, and biological treatment. Biol Psychiatry. 2002; 52(3):253–264.
14. Robinson RG, Starr LB, Lipsey JR, Rao K, Price TR. A two-year longitudinal study of post-stroke mood disorders: dynamic changes in associated variables over the first six months of follow-up. Stroke. 1984; 15(3):510–517.
15. Ayerbe L, Ayis S, Crichton S, Wolfe CD, Rudd AG. The natural history of depression up to 15 years after stroke: the South London Stroke Register. Stroke. 2013; 44(4):1105–1110.
16. De Ryck A, Brouns R, Fransen E, Geurden M, Van Gestel G, Wilssens I, et al. A prospective study on the prevalence and risk factors of poststroke depression. Cerebrovasc Dis Extra. 2013; 3(1):1–13.
17. Ouimet MA, Primeau F, Cole MG. Psychosocial risk factors in poststroke depression: a systematic review. Can J Psychiatry. 2001; 46(9):819–828.
18. Carson AJ, MacHale S, Allen K, Lawrie SM, Dennis M, House A, et al. Depression after stroke and lesion location: a systematic review. Lancet. 2000; 356(9224):122–126.
19. Bhogal SK, Teasell R, Foley N, Speechley M. Lesion location and poststroke depression: systematic review of the methodological limitations in the literature. Stroke. 2004; 35(3):794–802.
20. Wei N, Yong W, Li X, Zhou Y, Deng M, Zhu H, et al. Post-stroke depression and lesion location: a systematic review. J Neurol. 2015; 262(1):81–90.
21. Feng C, Fang M, Liu XY. The neurobiological pathogenesis of poststroke depression. Scientific World Journal. 2014; 2014:521349.
22. Hackett ML, Anderson CS, House A, Xia J. Interventions for treating depression after stroke. Cochrane Database Syst Rev. 2008; 8(4):CD003437.
23. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, et al. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev. 2012; 11:Cd009286.
24. Robinson RG, Schultz SK, Castillo C, Kopel T, Kosier JT, Newman RM, et al. Nortriptyline versus fluoxetine in the treatment of depression and in short-term recovery after stroke: a placebo-controlled, double-blind study. Am J Psychiatry. 2000; 157(3):351–359.
25. Dahmen N, Marx J, Hopf HC, Tettenborn B, Roder R. Therapy of early poststroke depression with venlafaxine: safety, tolerability, and efficacy as determined in an open, uncontrolled clinical trial. Stroke. 1999; 30(3):691–692.
26. Dupuy JM, Ostacher MJ, Huffman J, Perlis RH, Nierenberg AA. A critical review of pharmacotherapy for major depressive disorder. Int J Neuropsychopharmacol. 2011; 14(10):1417–1431.
27. Shin TK, Kang MS, Lee HY, Seo MS, Kim SG, Kim CD, et al. Fluoxetine and sertraline attenuate postischemic brain injury in mice. Korean J Physiol Pharmacol. 2009; 13(3):257–263.
28. Li WL, Cai HH, Wang B, Chen L, Zhou QG, Luo CX, et al. Chronic fluoxetine treatment improves ischemia-induced spatial cognitive deficits through increasing hippocampal neurogenesis after stroke. J Neurosci Res. 2009; 87(1):112–122.
29. Kimura M, Robinson RG, Kosier JT. Treatment of cognitive impairment after poststroke depression : a double-blind treatment trial. Stroke. 2000; 31(7):1482–1486.
30. Narushima K, Chan KL, Kosier JT, Robinson RG. Does cognitive recovery after treatment of poststroke depression last? A 2-year follow-up of cognitive function associated with poststroke depression. Am J Psychiatry. 2003; 160(6):1157–1162.
31. Jorge RE, Acion L, Moser D, Adams HP Jr, Robinson RG. Escitalopram and enhancement of cognitive recovery following stroke. Arch Gen Psychiatry. 2010; 67(2):187–196.
32. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, et al. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol. 2011; 10(2):123–130.
33. Narushima K, Robinson RG. The effect of early versus late antidepressant treatment on physical impairment associated with poststroke depression: is there a time-related therapeutic window? J Nerv Ment Dis. 2003; 191(10):645–652.
34. Grade C, Redford B, Chrostowski J, Toussaint L, Blackwell B. Methylphenidate in early poststroke recovery: a double-blind, placebo-controlled study. Arch Phys Med Rehabil. 1998; 79(9):1047–1050.
35. National Collaborating Centre for Mental H. National Institute for Health and Clinical Excellence: Guidance. Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society, Copyright (c) The British Psychological Society & The Royal College of Psychiatrists;2010.
36. Moret C. Combination/augmentation strategies for improving the treatment of depression. Neuropsychiatr Dis Treat. 2005; 1(4):301–309.
37. Lincoln NB, Flannaghan T, Sutcliffe L, Rother L. Evaluation of cognitive behavioural treatment for depression after stroke: a pilot study. Clin Rehabil. 1997; 11(2):114–122.
38. Mitchell PH, Veith RC, Becker KJ, Buzaitis A, Cain KC, Fruin M, et al. Brief psychosocial-behavioral intervention with antidepressant reduces poststroke depression significantly more than usual care with antidepressant: living well with stroke: randomized, controlled trial. Stroke. 2009; 40(9):3073–3078.
39. Lui MH, Ross FM, Thompson DR. Supporting family caregivers in stroke care: a review of the evidence for problem solving. Stroke. 2005; 36(11):2514–2522.
40. Currier MB, Murray GB, Welch CC. Electroconvulsive therapy for post-stroke depressed geriatric patients. J Neuropsychiatry Clin Neurosci. 1992; 4(2):140–144.
41. Kim BR, Kim DY, Chun MH, Yi JH, Kwon JS. Effect of repetitive transcranial magnetic stimulation on cognition and mood in stroke patients: a double-blind, sham-controlled trial. Am J Phys Med Rehabil. 2010; 89(5):362–368.
42. Jorge RE, Moser DJ, Acion L, Robinson RG. Treatment of vascular depression using repetitive transcranial magnetic stimulation. Arch Gen Psychiatry. 2008; 65(3):268–276.
43. Meron D, Hedger N, Garner M, Baldwin DS. Transcranial direct current stimulation (tDCS) in the treatment of depression: Systematic review and meta-analysis of efficacy and tolerability. Neurosci Biobehav Rev. 2015; 57:46–62.
44. Chen Y, Patel NC, Guo JJ, Zhan S. Antidepressant prophylaxis for poststroke depression: a meta-analysis. Int Clin Psychopharmacol. 2007; 22(3):159–166.
45. Hackett ML, Anderson CS, House A, Halteh C. Interventions for preventing depression after stroke. Cochrane Database Syst Rev. 2008; (3):Cd003689.
46. Salter KL, Foley NC, Zhu L, Jutai JW, Teasell RW. Prevention of poststroke depression: does prophylactic pharmacotherapy work? J Stroke Cerebrovasc Dis. 2013; 22(8):1243–1251.